Is the future scarless? - Fibroblasts as targets for scarless wound healing: a narrative review.

Scars, burns & healing Pub Date : 2022-09-01 eCollection Date: 2022-01-01 DOI:10.1177/20595131221095348
Dylan Parry, Keith Allison
{"title":"Is the future scarless? - Fibroblasts as targets for scarless wound healing: a narrative review.","authors":"Dylan Parry,&nbsp;Keith Allison","doi":"10.1177/20595131221095348","DOIUrl":null,"url":null,"abstract":"<p><p><b>Introduction:</b> Scarless healing is the ideal outcome of wound healing and is exhibited in some species. This narrative review assembles the current understanding of fibroblast heterogenicity along with the latest fibroblast-related targets for scar reduction therapies. Human regenerative wound healing is deemed possible due to the wound regeneration already seen in the early gestation foetus. <b>Methods:</b> This literature narrative review was undertaken by searching PubMed and Web of Science databases and Google Scholar to find articles concerning the fibroblast involvement in wound healing. We evaluated and collated these articles to form a consensus of the current understanding of the field. <b>Discussion:</b> This article describes current understanding of fibroblast heterogenicity and involvement in wound healing, focusing on the role of fibroblasts during physiological scarring. We also present the current most promising targets involving fibroblasts in the reduction of scarring and how we can manipulate the behaviour of fibroblasts to mimic the wound regeneration models in the human foetus. These targets include the pro-fibrotic EN1 positive fibroblast lineage, TGFβ1 inhibition, and genetic therapies utilising miRNAs and siRNAs. <b>Conclusion:</b> No therapies are currently available to eradicate scarring; however, treatment options are available to reduce the appearance of scarring. Further research into the heterogenicity and interactions of fibroblasts in both the foetus and adult is needed, and this may lead to the development of novel treatments against scarring.</p><p><strong>Lay summary: </strong>Scarless healing refers to the repair of a wound with minimal residual scarring. The main cell responsible for the repair process is the fibroblast. It is now understood that there are different types of fibroblasts. Simply, some of these fibroblasts lead to scarring and some lead to regeneration. The early human foetus has mainly regenerative fibroblasts, but during aging the number of scarring fibroblasts increase to become the majority in the adult . Understanding how we can modify this process may ultimately result in the reduction in scarring. Currently, scar reduction therapies are aimed at optimal wound healing, surgical removal of abnormal scars, and using steroids and other drugs to encourage better wound repair by limiting the effect of scarring fibroblasts. Future therapies aim to target specific groups of fibroblasts to encourage regenerative wound healing. This narrative review aims to cover the current understanding of the different groups of fibroblasts and their effect on wound healing. We also cover the current and potential therapies that can be used to reduce scarring and suggest further areas for research in this field.</p>","PeriodicalId":21495,"journal":{"name":"Scars, burns & healing","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445533/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scars, burns & healing","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/20595131221095348","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Scarless healing is the ideal outcome of wound healing and is exhibited in some species. This narrative review assembles the current understanding of fibroblast heterogenicity along with the latest fibroblast-related targets for scar reduction therapies. Human regenerative wound healing is deemed possible due to the wound regeneration already seen in the early gestation foetus. Methods: This literature narrative review was undertaken by searching PubMed and Web of Science databases and Google Scholar to find articles concerning the fibroblast involvement in wound healing. We evaluated and collated these articles to form a consensus of the current understanding of the field. Discussion: This article describes current understanding of fibroblast heterogenicity and involvement in wound healing, focusing on the role of fibroblasts during physiological scarring. We also present the current most promising targets involving fibroblasts in the reduction of scarring and how we can manipulate the behaviour of fibroblasts to mimic the wound regeneration models in the human foetus. These targets include the pro-fibrotic EN1 positive fibroblast lineage, TGFβ1 inhibition, and genetic therapies utilising miRNAs and siRNAs. Conclusion: No therapies are currently available to eradicate scarring; however, treatment options are available to reduce the appearance of scarring. Further research into the heterogenicity and interactions of fibroblasts in both the foetus and adult is needed, and this may lead to the development of novel treatments against scarring.

Lay summary: Scarless healing refers to the repair of a wound with minimal residual scarring. The main cell responsible for the repair process is the fibroblast. It is now understood that there are different types of fibroblasts. Simply, some of these fibroblasts lead to scarring and some lead to regeneration. The early human foetus has mainly regenerative fibroblasts, but during aging the number of scarring fibroblasts increase to become the majority in the adult . Understanding how we can modify this process may ultimately result in the reduction in scarring. Currently, scar reduction therapies are aimed at optimal wound healing, surgical removal of abnormal scars, and using steroids and other drugs to encourage better wound repair by limiting the effect of scarring fibroblasts. Future therapies aim to target specific groups of fibroblasts to encourage regenerative wound healing. This narrative review aims to cover the current understanding of the different groups of fibroblasts and their effect on wound healing. We also cover the current and potential therapies that can be used to reduce scarring and suggest further areas for research in this field.

Abstract Image

Abstract Image

Abstract Image

未来是没有疤痕的吗?-成纤维细胞作为无疤痕伤口愈合的靶点:综述。
简介:无疤痕愈合是创面愈合的理想结果,在一些物种中表现出来。本文综述了目前对成纤维细胞异质性的理解以及最新的疤痕减少治疗的成纤维细胞相关靶点。人类伤口再生愈合被认为是可能的,因为伤口再生已经在早期妊娠胎儿中看到。方法:通过检索PubMed、Web of Science数据库和Google Scholar检索有关成纤维细胞参与创面愈合的文献,进行文献叙述性综述。我们对这些文章进行了评估和整理,以形成对该领域当前理解的共识。讨论:本文描述了目前对成纤维细胞异质性和参与伤口愈合的理解,重点是成纤维细胞在生理性瘢痕形成中的作用。我们还介绍了目前最有希望的目标,包括减少疤痕的成纤维细胞,以及我们如何操纵成纤维细胞的行为来模拟人类胎儿的伤口再生模型。这些靶点包括促纤维化EN1阳性成纤维细胞谱系、tgf - β1抑制和利用mirna和sirna的遗传疗法。结论:目前尚无根治瘢痕的方法;然而,有一些治疗方法可以减少疤痕的出现。需要进一步研究成纤维细胞在胎儿和成人中的异质性和相互作用,这可能会导致新的治疗瘢痕形成的发展。摘要:无疤痕愈合是指伤口的修复与最小的残余疤痕。负责修复过程的主要细胞是成纤维细胞。现在人们知道成纤维细胞有不同的类型。简单地说,这些成纤维细胞中有些会导致疤痕,有些会导致再生。早期人类胎儿主要有再生成纤维细胞,但随着年龄的增长,瘢痕成纤维细胞的数量增加,成为成人中的大多数。了解我们如何改变这个过程可能最终导致疤痕的减少。目前,疤痕减少疗法的目的是优化伤口愈合,手术切除异常疤痕,并使用类固醇和其他药物通过限制瘢痕成纤维细胞的作用来促进更好的伤口修复。未来的治疗目标是针对特定的成纤维细胞群,以促进再生伤口愈合。这篇叙述性综述旨在涵盖目前对不同组的成纤维细胞及其对伤口愈合的影响的理解。我们还介绍了目前和潜在的治疗方法,可以用来减少疤痕,并提出了进一步的研究领域。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信